Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement Apr 13, 2017
Interpace Diagnostics Announces European Patent Approval For Underlying Technology of its ThyraMIR® microRNA Classifier Apr 3, 2017
Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2016 Financial Results, Business Progress Against Plan and Recent Accomplishments Mar 29, 2017
Interpace Diagnostics Group Announces Timing of Earnings Release and Investor Conference Call Mar 28, 2017
Interpace Diagnostics Group Announces Agreements to Successfully Restructure Debt and Terminate Royalty and Milestone Obligations Mar 23, 2017
